Cargando…

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction

AIM: The aim of this review was to summarize the ocular action of the most common phosphodiesterase (PDE) inhibitors used for the treatment of erectile dysfunction and the subsequent visual disorders. METHOD: This is a literature review of several important articles focusing on the pathophysiology o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moschos, Marilita M, Nitoda, Eirini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076796/ https://www.ncbi.nlm.nih.gov/pubmed/27799745 http://dx.doi.org/10.2147/DDDT.S118015

Ejemplares similares

Visual field examination using a video projector: comparison with Humphrey perimeter
por: Brouzas, Dimitrios, et al.
Publicado: (2014)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study
por: Moschos, Marilita M, et al.
Publicado: (2015)

The Impact of Chronic Tobacco Smoking on Retinal and Choroidal Thickness in Greek Population
por: Moschos, Marilita M., et al.
Publicado: (2016)

Response to: Comment on “The Impact of Chronic Tobacco Smoking on Retinal and Choroidal Thickness in Greek Population”
por: Moschos, Marilita M., et al.
Publicado: (2016)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Contact Lenses for Keratoconus- Current Practice
por: Moschos, Marilita M., et al.
Publicado: (2017)

Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study
por: Moschos, Marilita M, et al.
Publicado: (2016)

A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction
por: Lasker, George F., et al.
Publicado: (2010)

The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction:A systematic review
por: Atallah, Sandrine, et al.
Publicado: (2021)

Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders
por: Delhaye, Sébastien, et al.
Publicado: (2021)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

Physiology and Psychology of Vision and Its Disorders: A Review
por: Moschos, Marilita M
Publicado: (2014)

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
por: Raheem, Amr Abdel, et al.
Publicado: (2009)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
por: Carvalheira, Ana, et al.
Publicado: (2014)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
por: Yuan, Jin-Qiu, et al.
Publicado: (2016)

Erectile dysfunction treatment with phosphodiesterase-5 inhibitors: google trends analysis of last 10 years and covid-19 pandemic
por: Değer, Dr. Müslim D., et al.
Publicado: (2022)

Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction
por: Wang, Rui, et al.
Publicado: (2022)

Understanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunction
por: Campbell, Jeffrey, et al.
Publicado: (2017)

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2015)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
por: Cota, Jason M., et al.
Publicado: (2021)

Proniosomal Gel-Loaded Phosphodiesterase Inhibitors (Sildenafil, Vardenafil, and Tadalafil): Prospects for Topical Penile Therapy of Tadalafil for Treatment of Erectile Dysfunction
por: Mohamed, Soad A., et al.
Publicado: (2023)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction
por: Wang, Jian, et al.
Publicado: (2021)

Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
por: Haddad, Albert, et al.
Publicado: (2015)

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
por: Rosenberg, M T, et al.
Publicado: (2009)

Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil
por: Jannini, Emmanuele A., et al.
Publicado: (2018)

Tadalafil in the treatment of erectile dysfunction
por: Coward, Robert M, et al.
Publicado: (2008)

The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction
por: Cho, Min Chul, et al.
Publicado: (2019)

Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis
por: Yang, Jie, et al.
Publicado: (2021)

Carotid artery intima media thickness can predict the response to phosphodiesterase 5 inhibitors in patients with moderate erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b4i0vq536fh0adjro5uhu2qr4e